 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| PubChemCID | |
| ChemSpider | |
| Chemical and physical data | |
| Formula | C19H27BrN4O2 |
| Molar mass | 423.355 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ADB-5'Br-PINACA (5'-Br-ADB-PINACA) is anindazole-3-carboxamide basedsynthetic cannabinoid receptor agonist that has been sold as adesigner drug. It was first identified inAbu Dhabi in September 2022[1] but has subsequently been found in the US and Europe.[2] While formal pharmacology studies have not yet been carried out, ADB-5'Br-PINACA is believed to be a highly potent synthetic cannabinoid with similar potency to compounds such asMDMB-FUBINACA and5F-ADB, which have been responsible for numerous fatal and non-fataldrug overdoses, consistent with previously reported compounds from the patent literature showing bromination of the indazole ring at the 5-, 6-, or 7- positions to increase potency over the unsubstituted analogues.[3] ADB-5'Br-PINACA is the 5'-bromo analog ofADB-PINACA.
ADB-5'Br-PINACA can be synthesized from a "half finished" synthesis precursor known as ADB-5-Br-INACA, related toMDMB-5Br-INACA.[4]
ADB-5'Br-PINACA is not specifically scheduled in the United States at the federal level as of October 20, 2023 but may be considered illegal under thefederal analogue act if intended for consumption as a structural analog of the Schedule I cannabinoidADB-PINACA.
 | Thiscannabinoid related article is astub. You can help Wikipedia byexpanding it. |